Research ended
Forte Biosciences, Inc. (FBRX) was acquired by argenx for $77.00 a share in cash on 27 August 2026.
Our research on Forte Biosciences, Inc. ended on . Once a takeover closes, the shares stop trading under FBRX and there is nothing left to research. The last note, from , is below.
We keep this page so links to it still work and what we published about the stock stays on the record.
The last thesis
Forte Biosciences' common stock no longer trades: argenx completed its $77.00-per-share cash acquisition on 27 August 2026, so no case remains unless Nasdaq restores the listing or a Delaware court sets a value above $77.00.